Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with NVIDIA
Quantum-Si (Nasdaq: QSI) announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance its core technologies using NVIDIA AI and accelerated computing. The partnership aims to enhance data processing speeds to handle increased data volume from Proteus. By combining NVIDIA's computing capabilities with Quantum-Si's single-molecule protein sequencing technologies, they plan to develop a robust data processing system for generating protein insights to advance research, drug discovery, and healthcare AI. The company is already utilizing NVIDIA BioNeMo for protein structure prediction tools.
Quantum-Si (Nasdaq: QSI) ha annunciato una collaborazione con NVIDIA per sviluppare la sua nuova piattaforma proteomica, Proteus™, e migliorare le sue tecnologie di base utilizzando l'AI di NVIDIA e il calcolo accelerato. L'obiettivo della partnership è aumentare la velocità di elaborazione dei dati per gestire il volume crescente di dati provenienti da Proteus. Combinando le capacità computazionali di NVIDIA con le tecnologie di sequenziamento di proteine a singola molecola di Quantum-Si, intendono sviluppare un sistema robusto di elaborazione dei dati per generare informazioni sulle proteine che possano avanzare la ricerca, la scoperta di farmaci e l'AI in sanità. L'azienda sta già utilizzando NVIDIA BioNeMo per strumenti di previsione della struttura proteica.
Quantum-Si (Nasdaq: QSI) anunció una colaboración con NVIDIA para desarrollar su nueva plataforma de proteómica, Proteus™, y avanzar en sus tecnologías centrales utilizando la inteligencia artificial y la computación acelerada de NVIDIA. La asociación tiene como objetivo mejorar la velocidad de procesamiento de datos para manejar el aumento del volumen de datos de Proteus. Al combinar las capacidades de computación de NVIDIA con las tecnologías de secuenciación de proteínas de molécula única de Quantum-Si, planean desarrollar un sistema robusto de procesamiento de datos para generar conocimientos sobre proteínas que avancen la investigación, el descubrimiento de fármacos y la inteligencia artificial en salud. La empresa ya está usando NVIDIA BioNeMo para herramientas de predicción de la estructura de proteínas.
Quantum-Si (Nasdaq: QSI)가 NVIDIA와 협력하여 새로운 단백질체 플랫폼인 Proteus™를 개발하고 NVIDIA AI 및 가속 컴퓨팅을 사용하여 핵심 기술을 발전시키기로 발표했습니다. 파트너십의 목표는 Proteus로부터 증가하는 데이터 양을 처리하기 위한 데이터 처리 속도를 향상시키는 것입니다. NVIDIA의 컴퓨팅 능력과 Quantum-Si의 단분자 단백질 서열 분석 기술을 결합함으로써, 연구, 약물 발견 및 헬스케어 AI를 진전시키기 위한 단백질 통찰력을 생성하기 위한 강력한 데이터 처리 시스템을 개발할 계획입니다. 회사는 이미 단백질 구조 예측 도구를 위해 NVIDIA BioNeMo를 활용하고 있습니다.
Quantum-Si (Nasdaq: QSI) a annoncé une collaboration avec NVIDIA pour développer sa nouvelle plateforme de protéomique, Proteus™, et faire progresser ses technologies de base en utilisant l'IA de NVIDIA et l'informatique accélérée. L'objectif de ce partenariat est d'améliorer la vitesse de traitement des données pour gérer l'augmentation du volume de données provenant de Proteus. En combinant les capacités de calcul de NVIDIA avec les technologies de séquençage de protéines à molécule unique de Quantum-Si, ils prévoient de développer un système robuste de traitement des données pour générer des informations sur les protéines afin de faire avancer la recherche, la découverte de médicaments et l'IA dans le domaine de la santé. L'entreprise utilise déjà NVIDIA BioNeMo pour des outils de prédiction de la structure des protéines.
Quantum-Si (Nasdaq: QSI) gab bekannt, dass sie eine Zusammenarbeit mit NVIDIA angekündigt haben, um ihre neue Proteomik-Plattform Proteus™ zu entwickeln und ihre Kerntechnologien unter Verwendung von NVIDIA AI und beschleunigtem Rechnen voranzubringen. Ziel der Partnerschaft ist es, die Datenverarbeitungsgeschwindigkeiten zu verbessern, um das wachsende Datenvolumen von Proteus zu bewältigen. Durch die Kombination der Rechenfähigkeiten von NVIDIA mit den Technologien zur Einzelmolekül-Proteinsequenzierung von Quantum-Si planen sie, ein robustes Datenverarbeitungssystem zu entwickeln, um Erkenntnisse über Proteine zu generieren, die Forschung, Arzneimittelentdeckung und KI im Gesundheitswesen vorantreiben sollen. Das Unternehmen nutzt bereits NVIDIA BioNeMo für Werkzeuge zur Vorhersage der Proteinstruktur.
- Strategic partnership with major tech company NVIDIA
- Development of new proteomics platform Proteus
- Enhanced data processing capabilities for handling larger data volumes
- Integration of advanced AI technology for protein research
- None.
Insights
This collaboration with NVIDIA marks a significant technological leap for Quantum-Si's protein sequencing capabilities. The integration of NVIDIA's AI and accelerated computing infrastructure with QSI's Proteus platform addresses a critical bottleneck in proteomics - data processing speed and efficiency. The partnership leverages NVIDIA BioNeMo for both cloud and on-premises applications, which should substantially improve biomolecule design and analysis capabilities.
From a market perspective, this alliance strengthens QSI's competitive position in the rapidly growing proteomics market. The ability to process larger volumes of protein sequencing data more efficiently could accelerate research timelines and potentially lead to faster drug discovery processes. However, the financial impact remains speculative as no specific monetary terms were disclosed.
Collaboration will Drive AI-Powered Advancements in Next-Generation Protein Sequencing™ and Accelerated Data Processing
This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si’s advanced single-molecule protein sequencing and detection technologies, the collaboration aims to develop a robust data processing system. This system will keep pace with Quantum-Si’s rapidly evolving technology advancements, generating single-molecule protein insights to deepen our understanding of the proteome and develop innovative solutions through research, drug discovery, and healthcare AI.
“We are thrilled to collaborate with NVIDIA to make single-molecule proteomics more accessible to researchers,” said John Vieceli, Ph.D., Chief Product Officer of Quantum-Si. We have been leveraging AI protein structure prediction tools with NVIDIA BioNeMo, both in the cloud and on-premises to design new and improved biomolecules. Now, we are excited to apply NVIDIA technology for downstream data processing and interpretation applications for Proteus.
“Sequencing proteins to derive insights requires advanced processing capabilities that can handle vast volumes of data,” said George Vacek, Global Head of Genomics Alliances at NVIDIA. “Applying NVIDIA technology for accelerated computing and AI, Quantum-Si’s platform for proteomics and multi-omics can make a significant impact on healthcare and life sciences AI and research.”
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120405534/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is the purpose of Quantum-Si's collaboration with NVIDIA?
How will NVIDIA's technology benefit Quantum-Si's (QSI) Proteus platform?
What are the main applications of Quantum-Si's (QSI) enhanced protein sequencing platform?
